Remdesivir price slashed by 25-70%
Our Bureaus
New Delhi/Hyderabad/Bengaluru |
Updated on
April 17, 2021
× As reports of shortages and black-marketing of antiviral Remdesivir come in from across the country, the Centre intervened to make the injectable more affordable for patients.
Seven companies licensed to make the drug in India have “voluntarily lowered” their prices per 100mg/vial, in the range of 25-70 per cent. The companies include Cadila Healthcare, Syngene International, Dr Reddy’s Laboratories, Cipla, Mylan, Jubilant Generics and Hetero Healthcare, a note from the National Pharmaceutical Pricing Authority said.
States crack down
This, even as Andhra Pradesh cracked the whip and capped Remdesivir price at ₹2,500 for 100mg; Karnataka threatened action against black-marketeers, and Maharashtra started a toll-free number for patients needing the drug.
Updated Apr 17, 2021 | 20:35 IST
Drug companies like Cadila Healthcare, Dr Reddy s Laboratories, and Cipla have cut the prices of their respective brands of Remdesivir injection (100 mg/vial). Remdesivir
New Delhi: To enhance the availability of Remdesivir injection, used in the treatment of COVID-19, pharmaceutical companies have reduced the price following the government s intervention, the National Pharmaceutical Pricing Authority (NPPA) said on Saturday.
Drug companies like Cadila Healthcare, Dr Reddy s Laboratories, and Cipla have cut the prices of their respective brands of Remdesivir injection (100 mg/vial). The antiviral drug is used in the treatment of COVID-19.
Union Chemicals and Fertilizers Minister Sadananda Gowda hailed the decision taken by the drug companies.
NPPA directs reduction in Remdesivir price
By IANS |
2 Views
Bring Remdesivir under drug price control: Maha Barrister. Image Source: IANS News
New Delhi, April 16 : The National Pharmaceutical Pricing Authority (NPPA) has asked manufacturers of Covid drug Remdesivir to implement the revised MRP through a voluntary reduction of prices.
In a letter to Cadila Healthcare, Cipla Limited, Dr Reddy s Labs, Hetero Drugs, Jubilant Pharma, Mylan Labs and Syngene International, the NPPA has sought compliance of revised MRP with respect to Remdesivir as per the DPCO, 2013. Based on the Form-V furnished regarding voluntary reduction in Maximum Retail Price (MRP) of Remdesivir, manufactures/marketers of Remdesivir are hereby directed to implement the revised MRP throughout the distribution chain w.e.f. 15.04.2021, irrespective of the batch numbers, the NPPA said.
URL copied
Major manufacturers of Remdisivir have reduced the price considerably. (Photo for representation only)
The demand for Remdesivir, an injectable medicine, has soared manifold amid skyrocketing coronavirus cases in the country. Amid reports of several states pressing the alarm button over the acute shortage of the key antiviral drug, manufacturers have now decided to reduce the price.Â
Union Minister for Chemicals and Fertilizers DV Sadananda Gowda on Friday said that major manufacturers of Remdisivir have reduced the price considerably. On Govtâs intervention, major manufacturers of Remdesivir have voluntarily reduced its MRP ranging from Rs 5400 to less than Rs 3500 by 15.04.2021. This will support PM @narendramodi s efforts to fight #COVID19, Gowda said in his tweet.